Valsartan: Preclinical and Clinical Profile of an Antihypertensive Angiotensin‐II Antagonist

Cardiovascular Drug Reviews

Volumn 13, Issue 3, 1995, Pages 230-250

  Criscione, Leoluca ^a   Bradley, William A ^a   Bühlmayer, Peter ^a   Whitebread, Steve ^a   Glazer, Robert ^a   Lloyd, Peter ^a   Mueller, Philipp ^a   de Gasparo, Marc ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

Angiotensin II; Antihypertensive; AT1 receptor; Hypertension; Pharmacodynamic; Pharmacokinetic; Renal hypertensive rats; Review; Telemetry; Valsartan

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; VALSARTAN;

BILE FLOW; BLOOD PRESSURE; CLINICAL TRIAL; COUGHING; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; DRUG EXCRETION; DRUG METABOLISM; DRUG POTENCY; DRUG SAFETY; ESSENTIAL HYPERTENSION; FATIGUE; HEADACHE; HUMAN; HYPERTENSION; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MARMOSET; NONHUMAN; ORAL DRUG ADMINISTRATION; PHARMACODYNAMICS; PRIORITY JOURNAL; REVIEW; SYSTOLIC BLOOD PRESSURE; TACHYCARDIA; VERTIGO;

EID: 0029549912     PISSN: 08975957     EISSN: 15273466     Source Type: Journal    
DOI: 10.1111/j.1527-3466.1995.tb00305.x     Document Type: Article

References (49)

1. Angiotensin II antagonists: Patent activity since the discovery of DuP‐753
2. Valsartan, a potent, orally active angiotensin II antagonist developed from the structurally new amino acid series
3. Dopamine selectively inhibits aldosterone responses to angiotensin II in humans
4. In vitro pharmacology of L‐158,809, anew highly potent and selective angiotensin II receptor antagonist
5. Pharmacological profile of valsartan: A potent, orally active, nonpeptide antagonist of the angiotensin II AT1‐receptor subtype
6. Characteristics of angiotensin II receptors and their role in cell and organ physiology
7. A proposed update of the nomenclature of angiotensin receptors
8. The angiotensin II AT2 receptor subtype
9. Binding of valsartan to mammalian AT1 receptors
10. Pharmacology of angiotensin II receptor subtypes
11. Acute, subacute and chronic toxicity of the new angiotensin converting enzyme inhibitor ramipril
12. The discovery of DuP 753, a potent, orally active nonpeptide angiotensin II receptor antagonist
13. H3]losartan in the rat liver
14. Angiotensin II receptor binding inhibitors
15. The renin‐angiotensin system: Inhibitors and antagonists
16. Angiotensin, ACE‐inhibitors and endothelial control of vasomotor tone
17. Endothelium‐dependent vasomotion in aging, hypertension, and heart failure
18. Renal effects of enalapril in dogs
19. TCV‐116: A new angiotensin II type‐1 receptor antagonist
20. Angiotensin II receptor blockade with single doses of valsartan in healthy, normotensive subjects
21. Angiotensin converting enzyme inhibitors: An overview
22. Juxtaglomerular cell hypertrophy and hyperplasia induced in rhesus monkeys by angiotensin receptor antagonists
23. Historical development of saralasin
24. Role of the pressor action of angiotensin II in experimental hypertension
25. Angiotensin‐converting enzyme inhibition in congestive heart failure‐benefit and perspective
26. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial
27. Use of angiotensin II antagonists in human heart failure: Function of the subtype 1 receptor
28. Agonist‐antagonist interactions at angiotensin receptors‐application of a two‐state receptor model
29. Expression of components of the ras during prolonged blockade at different levels in primates
30. Reversal of cardiac hypertrophy in renal hypertensive rats: Medical vs. surgical therapy
31. Pharmacology of nonpeptide angiotensin II receptor antagonists
32. Nonpeptide angiotensin II receptor antagonists
33. Angiotensin II antagonist CGP 48933 (valsartan)—Ergebnisse einer doppelblinden, plazebokontrollierten Multicenter‐Studie
34. Renal morphology and function in dogs after treatment with the angiotensin‐converting enzyme inhibitor quinapril
35. Angiotensin II receptors and functional correlates
36. The discovery and physiological effects of a new class of highly specific angiotensin II receptor antagonists
37. Nonpeptide angiotensin II receptor antagonists
38. Antihypertensive therapy augments endo‐thelium‐dependent relaxations in coronary arteries of spontaneously hypertensive rats
39. Angiotensin‐converting enzyme inhibition prolongs survival and modifies the transition to heart failure in rats with pressure overload hypertrophy due to ascending aortic stenosis
40. Rationale for the chemical development of angiotensin II receptor antagonists
41. 3H]DuP 753 (losartan) to rat liver homogenates reveals multiple sites. Relationship to AT1a‐ and AT1b‐type angiotensin receptors and novel nonangiotensin binding sites
42. Pharmacology of DuP 532, a selective and noncompetitive ATI receptor antagonist
43. Losartan (DuP 753). an orally active nonpeptide angiotensin II receptor antagonist
44. Enhancement of losartan (DuP 753)‐induced angiotensin II receptor antagonism by PD123177 in rats
45. Nonpeptide angiotensin II receptor antagonists. IX. Antihypertensive activity in rats of DuP 753, an orally active antihypertensive agent
46. Nonpeptide angiotensin II receptor antagonists. XL Pharmacology of EXP3174: An active metabolite of DuP 753. an orally active antihypertensive agent
47. Hyperplasia of juxtaglomerular cells and renin localization in kidneys of normotensive animals given captopril
48. Comparison of the effects of angiotensin convening enzyme inhibition and ATI blockade on left ventricular structure and function in renal hypertensive rats as determined by magnetic resonance imaging